ReviewAdvances in experimental medicine and biology2026
Innovative Biomarkers for Oral Immunity: Advancements and Clinical Applications.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral immunity is an essential barrier for protection against pathogens, supporting oral health, and overall health-related challenges. Nevertheless, dysregulation of oral immunity results in different pathological conditions that are often challenging to diagnose and manage. Biomarkers have revolutionized the management of oral health by offering information about molecular and cellular immune events, disease etiology, and treatment outcomes. This review focuses on the biomarkers for oral immunity in the context of the existing trends and includes genetic, proteomic, metabolomic, and microbiome biomarkers. Single-nucleotide polymorphism (SNP) and copy number variation (CNV) have improved the knowledge of the genetic risk factors for oral diseases and the treatment plan for patients. Cytokines, matrix metalloproteinases (MMPs), and antimicrobial peptides (AMPs) have enhanced the diagnostic accuracy of diseases, prognostication, and evaluation of therapeutic efficacy. Metabolomic biomarkers have provided valuable insights into the biochemical pathways related to oral health and diseases, while microbiome-derived biomarkers have revealed the intricate host-microbiota interactions. Recent developments in high-throughput screening, multi-omics, and computational biology have facilitated the identification of biomarkers of oral immunity. These molecular markers have been proven to have the potential for screening, prognosis, and targeted therapy of oral diseases such as periodontitis, oral cancer, and autoimmune diseases. However, some issues are still to be solved, such as standardization of biomarker usage, obtaining the approval of biomarkers by different authorities, and the economic issues regarding the application of biomarkers for clinical diagnostics.
Indexed as
Identifiers
41225127What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.